Second Quarter of Fiscal 2020 Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020-
-Trogarzo net revenues up 13.2% and combined EGRIFTA, EGRIFTA SV net revenues up 7.3% over Q2 2019-
-Supply chain and product inventory remain unaffected by COVID-19 pandemic-
Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its financial results for the second quarter of fiscal 2020 ended May 31, 2020.